Literature DB >> 18086570

Melanoma cell sensitivity to Docetaxel-induced apoptosis is determined by class III beta-tubulin levels.

Nizar M Mhaidat1, Rick F Thorne, Charles Edo de Bock, Xu Dong Zhang, Peter Hersey.   

Abstract

We have previously shown that Docetaxel-induced variable degrees of apoptosis in melanoma. In this report, we studied the beta-tubulin repertoire of melanoma cell lines and show that class III beta-tubulin expression correlated with Docetaxel-resistance. Sensitive cells showed low levels of class III beta-tubulin with little microtubular incorporation, whereas class III beta-tubulin expression was higher in resistant cells and was incorporated into the cytoskeleton. As proof of concept, abrogation of class III by siRNA reverted Docetaxel-resistant cells to a sensitive phenotype, restoring the microtubular polymerisation response and promoting high levels of apoptosis through Bax activation. These results suggest that phenotypic expression of beta-tubulin class III in melanoma may help identify patients with melanoma that can respond to taxanes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18086570     DOI: 10.1016/j.febslet.2007.12.014

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  11 in total

1.  GRP78 regulates sensitivity of human colorectal cancer cells to DNA targeting agents.

Authors:  Nizar M Mhaidat; Karem H Alzoubi; Omar F Khabour; Mohammed N Banihani; Qosay A Al-Balas; Sulaiman Swaidan
Journal:  Cytotechnology       Date:  2014-11-16       Impact factor: 2.058

Review 2.  Microtubules and resistance to tubulin-binding agents.

Authors:  Maria Kavallaris
Journal:  Nat Rev Cancer       Date:  2010-02-11       Impact factor: 60.716

3.  Colchicine Binding Site Agent DJ95 Overcomes Drug Resistance and Exhibits Antitumor Efficacy.

Authors:  Kinsie E Arnst; Yuxi Wang; Zi-Ning Lei; Dong-Jin Hwang; Gyanendra Kumar; Dejian Ma; Deanna N Parke; Qiang Chen; Jinliang Yang; Stephen W White; Tiffany N Seagroves; Zhe-Sheng Chen; Duane D Miller; Wei Li
Journal:  Mol Pharmacol       Date:  2019-05-01       Impact factor: 4.436

4.  Class III beta-tubulin expression and in vitro resistance to microtubule targeting agents.

Authors:  C Stengel; S P Newman; M P Leese; B V L Potter; M J Reed; A Purohit
Journal:  Br J Cancer       Date:  2009-12-22       Impact factor: 7.640

Review 5.  Nanoparticle-mediated drug delivery for treating melanoma.

Authors:  Vaibhav Mundra; Wei Li; Ram I Mahato
Journal:  Nanomedicine (Lond)       Date:  2015-08-05       Impact factor: 5.307

6.  Potassium-3-beta-hydroxy-20-oxopregn-5-en-17-alpha-yl sulfate: a novel inhibitor of 78 kDa glucose-regulated protein.

Authors:  Nizar M Mhaidat; Qosay A Al-Balas; Karem H Alzoubi; Rowan F AlEjielat
Journal:  Onco Targets Ther       Date:  2016-02-03       Impact factor: 4.147

7.  Regulation of intestinal epithelial cells transcriptome by enteric glial cells: impact on intestinal epithelial barrier functions.

Authors:  Laurianne Van Landeghem; Maxime M Mahé; Raluca Teusan; Jean Léger; Isabelle Guisle; Rémi Houlgatte; Michel Neunlist
Journal:  BMC Genomics       Date:  2009-11-02       Impact factor: 3.969

8.  Caspase-2 promotes cytoskeleton protein degradation during apoptotic cell death.

Authors:  H Vakifahmetoglu-Norberg; E Norberg; A B Perdomo; M Olsson; F Ciccosanti; S Orrenius; G M Fimia; M Piacentini; B Zhivotovsky
Journal:  Cell Death Dis       Date:  2013-12-05       Impact factor: 8.469

Review 9.  An Emerging Role for Tubulin Isotypes in Modulating Cancer Biology and Chemotherapy Resistance.

Authors:  Amelia L Parker; Wee Siang Teo; Joshua A McCarroll; Maria Kavallaris
Journal:  Int J Mol Sci       Date:  2017-07-04       Impact factor: 5.923

10.  Class III β-Tubulin Overexpression Induces Chemoresistance to Eribulin in a Leiomyosarcoma Cell Line.

Authors:  Kenichiro Yahiro; Yoshihiro Matsumoto; Jun-Ichi Fukushi; Ken-Ichi Kawaguchi; Makoto Endo; Nokitaka Setsu; Keiichiro IIda; Suguru Fukushima; Makoto Nakagawa; Atsushi Kimura; Yoshinao Oda; Yasuharu Nakashima
Journal:  Anal Cell Pathol (Amst)       Date:  2018-06-21       Impact factor: 2.916

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.